Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Average Recommendation of “Reduce” by Brokerages

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been assigned an average rating of “Reduce” from the nine analysts that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $26.50.

A number of equities analysts have issued reports on IART shares. Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday. Bank of America decreased their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. Citigroup cut their price objective on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a report on Tuesday, October 1st. Morgan Stanley increased their target price on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. Finally, JMP Securities cut their price objective on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th.

Integra LifeSciences Stock Down 0.2 %

Integra LifeSciences stock opened at $19.76 on Friday. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $45.42. The company’s 50-day moving average is $19.07 and its 200-day moving average is $25.67. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The firm has a market capitalization of $1.56 billion, a PE ratio of 39.52, a P/E/G ratio of 0.62 and a beta of 1.09.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same period last year, the firm earned $0.71 EPS. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. Sell-side analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of large investors have recently made changes to their positions in IART. Blue Trust Inc. raised its stake in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares during the last quarter. CWM LLC lifted its stake in shares of Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after buying an additional 425 shares in the last quarter. Valley National Advisers Inc. acquired a new position in Integra LifeSciences during the first quarter worth $63,000. Canada Pension Plan Investment Board acquired a new position in Integra LifeSciences in the second quarter valued at approximately $114,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Integra LifeSciences by 58.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 1,711 shares during the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.